CN116234571A - 治疗视神经脊髓炎谱系障碍的方法 - Google Patents

治疗视神经脊髓炎谱系障碍的方法 Download PDF

Info

Publication number
CN116234571A
CN116234571A CN202180046409.5A CN202180046409A CN116234571A CN 116234571 A CN116234571 A CN 116234571A CN 202180046409 A CN202180046409 A CN 202180046409A CN 116234571 A CN116234571 A CN 116234571A
Authority
CN
China
Prior art keywords
subject
nmosd
need
concentration
sgfap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046409.5A
Other languages
English (en)
Chinese (zh)
Inventor
W·里斯
E·卡茨
M·史密斯
N·米特雷德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN116234571A publication Critical patent/CN116234571A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180046409.5A 2020-06-30 2021-06-30 治疗视神经脊髓炎谱系障碍的方法 Pending CN116234571A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US63/046133 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US63/052093 2020-07-15
US202063071092P 2020-08-27 2020-08-27
US63/071092 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
CN116234571A true CN116234571A (zh) 2023-06-06

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046409.5A Pending CN116234571A (zh) 2020-06-30 2021-06-30 治疗视神经脊髓炎谱系障碍的方法

Country Status (11)

Country Link
US (1) US20230406928A1 (enExample)
EP (1) EP4172211A4 (enExample)
JP (1) JP2023534916A (enExample)
KR (1) KR20230030642A (enExample)
CN (1) CN116234571A (enExample)
AU (1) AU2021299307A1 (enExample)
BR (1) BR112022026747A2 (enExample)
CA (1) CA3178954A1 (enExample)
IL (1) IL299381A (enExample)
MX (1) MX2022016236A (enExample)
WO (1) WO2022006283A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230097118A (ko) * 2020-10-29 2023-06-30 비엘라 바이오, 인크. 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020924A2 (pt) * 2019-04-24 2022-04-19 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar doença autoimune
KR20230097118A (ko) * 2020-10-29 2023-06-30 비엘라 바이오, 인크. 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용

Also Published As

Publication number Publication date
WO2022006283A2 (en) 2022-01-06
AU2021299307A1 (en) 2022-12-22
US20230406928A1 (en) 2023-12-21
MX2022016236A (es) 2023-03-29
EP4172211A2 (en) 2023-05-03
JP2023534916A (ja) 2023-08-15
WO2022006283A3 (en) 2022-02-03
EP4172211A4 (en) 2024-07-10
CA3178954A1 (en) 2022-01-06
IL299381A (en) 2023-02-01
KR20230030642A (ko) 2023-03-06
BR112022026747A2 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
Evoli et al. Therapeutic options in ocular myasthenia gravis
Akaishi et al. Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica
US20230406928A1 (en) Methods of treating neuromyelitis optica spectrum disorder
KR20220004113A (ko) 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
EP4426349A2 (en) Methods for treating alzheimer's disease
Dai et al. Rapid exacerbation of neuromyelitis optica after rituximab treatment
Choi et al. Clinical characteristics of optic neuritis in Koreans greater than 50 years of age
Fox et al. Thyroid eye disease: Management, Advances and Future Opportunities
HK40087593A (zh) 治疗视神经脊髓炎谱系障碍的方法
TW202317181A (zh) 治療視神經脊髓炎譜系障礙之方法
Kamijo et al. Successful maintenance therapy with intravenous immunoglobulin to reduce relapse attacks and steroid dose in a patient with refractory myelin oligodendrocyte glycoprotein antibody-positive optic neuritis
US20140234307A1 (en) Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
Wiśniewska et al. Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD)
Riboni Verri Visual Outcome Measures of Remyelination and Neuroprotection in Multiple Sclerosis
Gilad et al. Effect of time to initiation and dose of methylprednisolone on outcome in multiple sclerosis‐related optic neuritis
CN116583538A (zh) 使用抗cd19抗体治疗自身免疫性疾病
Chen et al. Optic Neuritis
Chen et al. Optic Neuritis
NEURITIS How far should I manage acute optic neuritis as an ophthalmologist? A United Kingdom perspective
Zhuang et al. Eculizumab for the acute attack of neuromyelitis optica spectrum disorder
Grzybowski et al. Treatment of optic neuritis
Sergeevna et al. Neuromyelitis spectrum disorders
JPWO2022094334A5 (enExample)
Alemu et al. Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087593

Country of ref document: HK